This polyamine blocking therapy might thus serves a better therapeutic benefit in breast cancer treatment than the use of monotherapy targeting polyamine pathway inhibition, however, there is a need to determine which breast cancer, based on the hormone receptor status, might benefit most from therapy that depletes intracellular polyamine content. This evidence concerns the gene NR4A1 and breast cancer.